Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Baylor Biosciences
China
- Ownership
- Private
- Development stage
- Other
01
Overview
Baylor Biosciences has in-licensed INOpulse, a pulsatile inhaled nitric oxide delivery system originally developed by Bellerophon Therapeutics, with rights to develop and commercialize it in Greater China for pulmonary hypertension associated with fibrotic interstitial lung disease, sarcoidosis, and COPD, leveraging Bellerophon's late-stage clinical data.[5][7][10]
- Therapeutic areas
- Pulmonology
- Modalities
- DeviceSmall molecule
- Industry
- Biotech
02
Partnerships
Bellerophon Therapeutics[5][7]
Beyond the preview
Go deeper on Baylor Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baylor Biosciences.